CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023
CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023
February 2, 2023 at 7:00 AM EST
Virtual
The presentations will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/
VONJO™ is a trademark of
Investor Relations and Media Contacts:
invest@ctibiopharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-participate-in-upcoming-investor-conferences-in-february-2023-301737063.html
SOURCE